Study of CPI-100 in Patients With Advanced Tumors


This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).

Full Title of Study: “A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 21, 2020

Detailed Description

Primary Objectives:

• To determine the safety, tolerability and maximum tolerated dose (MTD) of CPI-100 as once every two weeks (Q2W) and once every three weeks (Q3W) regimens in patients with advanced tumors

Secondary Objectives:

- To evaluate the pharmacokinetics (PK) of CPI-100

- To evaluate clinical response and resolution of symptoms after CPI-100 treatment

- To characterize adverse events of CPI-100 monotherapy and CPI-100 in combination with capecitabine in patients with advanced cancers

Up to 5 dose levels of CPI-100 Q2W, 4 dose levels of Q3W regimen of CPI-100 monotherapy (Q3W Arm A) and 4 dose levels of Q3W regimen of CPI-100 in combination with capecitabine (Q3W Arm B) will be tested in a dose escalation study. MTD will be defined as the dose associated with a dose limiting toxicity (DLT) in less than or equal to 33% of patients at the dose level tested. Dose limiting toxicity (DLT) is defined as one of the following events occurring from the intravenous injection of CPI-100 within 28 days (Q2W) or 42 days (Q3W):

- Grade 4 or greater treatment related adverse events

- Any Grade 3 or greater treatment related non-hematologic, non-dermatologic toxicity (including nausea, vomiting or diarrhea lasting more than 72 hours)


  • Drug: CPI-100
    • CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
  • Drug: Capecitabine
    • Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period

Arms, Groups and Cohorts

  • Experimental: CPI-100 Monotherapy
    • Dose Escalation Groups: CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group
  • Experimental: CPI-100 Combination with Capecitabine
    • CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)

Clinical Trial Outcome Measures

Primary Measures

  • Maximum Tolerated Dose (MTD)
    • Time Frame: 28 Days
    • • To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy as assessed by CTCAE5

Secondary Measures

  • Clinical Benefit
    • Time Frame: through study completion, an average of 4 months
    • • To assess clinical benefit by response rate and resolution of symptoms, which will be reported as response rate (%)
  • Adverse Effect
    • Time Frame: through study completion, an average of 4 months
    • • To assess adverse effect as either treatment-related or non-treatment-related as defined by CTCAE
  • Maximum Plasma Concentration (Cmax)
    • Time Frame: 8 Days
    • • To evaluate maximum plasma concentration (Cmax) of CPI-100 in patients tested
  • Area Under the Curve (AUC)
    • Time Frame: 8 Days
    • • To evaluate area under the curve (AUC) of CPI-100 in patients tested

Participating in This Clinical Trial

Inclusion Criteria

  • Have a histologically or cytologically confirmed diagnosis of advanced solid tumor
  • Have advanced or metastatic disease refractory to standard curative or palliative therapy or contraindication to standard therapy
  • Be reasonably recovered from preceding major surgery or no major surgery within 4 weeks prior to the start of Day 1 treatment
  • Have a negative pregnancy test for females with child bearing age at screening and should not be breast feeding
  • Be willing to abstain from sexual activity or practice physical barrier contraception from study entry to 6 months after the last day of treatment

Exclusion Criteria

  • Have peripheral neuropathy of Grade 3 or Grade 4 at screening
  • Have peripheral sensory neuropathy of Grade 2 or greater at screening
  • Have an interval from previous neurotoxic drugs less than 3 months unless reasonably recovered from all grades of neurotoxicity to grade 1 or lower as judged by the investigator
  • Have known hypersensitivity to chemotherapeutic agents
  • Have a history of thrombocytopenia with complications including hemorrhage or bleeding > Grade 2 that required medical intervention or any hemolytic condition or coagulation disorders that would make participation unsafe
  • Have unresolved toxicity from previous treatment or previous investigational agents; excluding alopecia
  • Is pregnant or breast-feeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Coordination Pharmaceuticals, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Ze-Qi Xu, Ph.D., (630) 415-5601,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.